Loading...
The clinical manifestations of Epstein-Barr virus- induced infectious mononucleosis (EBV-IM) range from trivial to life-threatening, with little clearcut benefit from either routine corticosteroid or antiviral treatment. To evaluate the utility of combination therapy, European researchers enrolled 94 young adults with newly diagnosed EBV-IM into a double-blind, placebo-controlled study.
Of 86 evaluable participants, 44 received high-dose acyclovir (800 mg five times daily for 10 days) and prednisolone (0.7 mg/kg daily for 4 days, then tapered over 6 subsequent days), and 42 received placebo. No significant differences in clinical endpoints such as sore throat, hepatosplenomegaly, fatigue, or depression emerged between these groups at any tim…